Results 21 to 30 of about 141,477 (341)

Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

New England Journal of Medicine, 2009
BACKGROUND Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel.
L. Wallentin, R. Becker, A. Budaj, C. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. Mahaffey, B. Scirica, A. Skene, P. Steg, R. Storey, R. Harrington, A. Freij, M. Thorsén   +17 more
semanticscholar   +1 more source

Systematic review and meta-analysis of optimal P2Y₁₂ blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome [PDF]

, 2016
Background: Patients with diabetes are at increased risk of acute coronary syndromes (ACS) and their mortality and morbidity outcomes are significantly worse following ACS events, independent of other comorbidities.
Brown, Oliver I, Hoye, Angela, Rossington, Jennifer A   +2 more
core   +1 more source

Prasugrel versus clopidogrel in patients with acute coronary syndromes.

New England Journal of Medicine, 2007
BACKGROUND Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention.
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano de Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman   +13 more
semanticscholar   +1 more source

Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study. [PDF]

, 2014
ObjectiveThere is insufficient evidence on which to base a recommendation for optimal antiplatelet therapy following a stroke while on aspirin. The objective was to compare clopidogrel initiation vs aspirin reinitiation for vascular risk reduction among ...
Chang, Ku-Chou, Lee, Hsuei-Chen, Lee, Jiann-Der, Lee, Meng, Lee, Tsong-Hai, Ovbiagele, Bruce, Rao, Neal M, Saver, Jeffrey L, Wang, Hui-Hsuan, Wu, Chih-Ying, Wu, Yi-Ling   +10 more
core   +1 more source

Clopidogrel-induced pneumonia [PDF]

BMJ Case Reports, 2021
A 75-year-old man was admitted to our hospital with progressive dyspnoea on effort and cough. Three months before presentation, he had undergone percutaneous coronary intervention for unstable angina. At that time, he began taking aspirin (100 mg daily) and clopidogrel (75 mg daily).
Yoshitaka Tomoda, Chinami Nagasawa, Yukikazu Awaya, Takashi Miyajima   +3 more
openaire   +3 more sources

Assessing a 600-mg Loading Dose of Clopidogrel 24 Hours Prior to Pipeline Embolization Device Treatment [PDF]

, 2018
Background: Clopidogrel/aspirin antiplatelet therapy routinely is administered 7-10 days before pipeline aneurysm treatment. Our study assessed the safety and efficacy of a 600-mg loading dose of clopidogrel 24 hours before Pipeline Embolization Device ...
Atallah, MD, Elias, Bekelis, MD, Kimon, Chalouhi, MD, Nohra, Hasan, MD, David, Jabbour, Pascal, MD, Rosenwasser, MD, MBA, FACS, FAHA, Robert H., Saad, MD, Hassan, Smith, MD, Michelle, Tjoumakaris, MD, Stavropoula, Zarzour, MD, Hekmat   +9 more
core   +2 more sources

Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.

New England Journal of Medicine, 2020
BACKGROUND The effect of single as compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication for long-term anticoagulation has not been ...
J. Brouwer, V. Nijenhuis, R. Delewi, R. Hermanides, W. Holvoet, C. Dubois, P. Frambach, B. de Bruyne, G. V. van Houwelingen, J. van der Heyden, P. Toušek, F. van der Kley, I. Buysschaert, C. Schotborgh, B. Ferdinande, P. van der Harst, J. Roosen, J. Peper, Frederick W F Thielen, L. Veenstra, D. R. Chan Pin Yin, M. Swaans, B. Rensing, A. W. van ’t Hof, L. Timmers, J. Kelder, P. Stella, J. Baan, J. T. ten Berg   +28 more
semanticscholar   +1 more source

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)

Molecules, 2021
Clopidogrel is a widely-used antiplatelet drug. It is important for the treatment and prevention of coronary heart disease. Clopidogrel can effectively reduce platelet activity and therefore reduce stent thrombosis.
Mohammed Ahmed Akkaif, N. Daud, A. Sha’aban, M. L. Ng, M. A. S. Abdul Kader, D. Noor, B. Ibrahim   +6 more
semanticscholar   +1 more source

Validation of a method for quantitation of the clopidogrel active metabolite, clopidogrel, clopidogrel carboxylic acid, and 2-oxo-clopidogrel in feline plasma [PDF]

Journal of Veterinary Cardiology, 2017
The clopidogrel active metabolite (CAM) is unstable and challenging to quantitate. The objective was to validate a new method for stabilization and quantitation of CAM, clopidogrel, and the inactive metabolites clopidogrel carboxylic acid and 2-oxo-clopiodgrel in feline plasma.Two healthy cats administered clopidogrel to demonstrate assay in vivo ...
Janne G. Lyngby, Michael H. Court, Pamela M. Lee   +2 more
openaire   +3 more sources

Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.

New England Journal of Medicine, 2020
BACKGROUND The roles of anticoagulation alone or with an antiplatelet agent after transcatheter aortic-valve implantation (TAVI) have not been well studied.
V. Nijenhuis, J. Brouwer, R. Delewi, R. Hermanides, W. Holvoet, C. Dubois, P. Frambach, B. de Bruyne, G. V. van Houwelingen, J. van der Heyden, P. Toušek, F. van der Kley, I. Buysschaert, C. Schotborgh, B. Ferdinande, P. van der Harst, J. Roosen, J. Peper, Frederick W F Thielen, L. Veenstra, D. R. Chan Pin Yin, M. Swaans, B. Rensing, A. W. van ’t Hof, L. Timmers, J. Kelder, P. Stella, J. Baan, J. T. ten Berg   +28 more
semanticscholar   +1 more source